Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
January 5, 2022- Requested indication focuses on patients whose respiratory failure has progressed despite treatment with Remdesivir or other approved therapies
NRx Pharmaceuticals (Nasdaq: NRXP) announced today that it has submitted an application for Emergency Use Authorization (EUA) to the US Food and Drug Administration (FDA) for the use of ZYESAMI®...
-
January 3, 2022- Invention by NRx scientists provides a path to long-term patent protection for ZYESAMI® (aviptadil)
NRx Pharmaceuticals (Nasdaq: NRXP) announced today that it has filed a provisional composition of matter patent application with the US Patent and Trademark Office entitled "Stable, Buffer-free...
-
December 28, 2021- Breakthrough Therapy Designation request focused on patients whose respiratory failure has progressed despite treatment with Remdesivir
NRx Pharmaceuticals (Nasdaq: NRXP) announced today that it has filed a new Breakthrough Therapy Designation (BTD) request with the US Food and Drug Administration (FDA) focused on patients with...
-
December 15, 2021•The Nasdaq Biotechnology Index (NBI) is a market index comprised of Nasdaq® listed Biotechnology and Pharmaceutical companies
RADNOR, Pa., Dec. 15, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP) today announced that Nasdaq (Nasdaq:NDAQ) has added the company to the Nasdaq Biotechnology Index (Nasdaq:NBI)...
-
December 14, 2021•After Review of More than 348 Enrolled Patients in ACTIV-3b Critical Care Study, No New Safety Concerns Identified by Independent Data Safety Monitoring Board; Study Cleared to Continue Enrollment to Target 640 Patients
RADNOR, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage, biopharmaceutical company, today provided a new safety update on ZYESAMI® (aviptadil), which...
-
December 9, 2021•NRx and Hungary Agree on Regulatory Path for Emergency Use of ZYESAMI
BUDAPEST, Hungary, Dec. 09, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP) today announced the conclusion of high-level meetings in Hungary that are expected to lead to utilization of...
-
December 6, 2021•Independent Data Safety Monitoring Board has completed review of BriLife phase 2 trial at low, medium, and high doses, with a formal report expected imminently
RADNOR, Pa., Dec. 06, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), today was advised that the independent Data Safety Monitoring Board overseeing the phase 2 trial of the...
-
November 29, 2021•Analysis was conducted in the subgroup of ZYESAMI- and placebo-treated patients who were previously treated with remdesivir in the COVID-AIV trial representing approximately 70 percent of the study population
RADNOR, Pa., Nov. 29, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP) announced today that it has completed an analysis to identify clinical evidence that indicates a substantial...
-
November 26, 2021•Analysis of Blood Samples from Patients who Responded to the BriLife® Vaccine During Phase 2 Trial Suggests that the Same Level of Response was Seen Against the Delta Variant as Against the Original “Wild-Type” Virus
RADNOR, Pa., Nov. 26, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), today notes that the Israel Institute for Biological Research (IIBR) has posted scientific results from an...
-
November 16, 2021
RADNOR, Pa., Nov. 16, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical-stage, biopharmaceutical company, today provided a business update and financial results for the...
-
November 12, 2021Conference Begins on November 15, 2021
RADNOR, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today announced its Chairman of the Board and Chief Executive...
-
November 11, 2021•US Food and Drug Administration Review Allows for High Volume Production of ZYESAMI® (aviptadil)
RADNOR, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), today announced receipt of the US Food and Drug Administration’s (FDA) response to NRx’s October 8 submission...
-
November 4, 2021- NRx Pharmaceuticals Has Requested a Type A Meeting with US Food and Drug Administration (FDA) to Include Treating Physicians and Patients
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company (NRx), today announced that the US Food and Drug Administration (FDA) has declined to issue an Emergency Use...
-
November 4, 2021- NRx Enters into Negotiations for Financing and Manufacturing Capacity with BNP Paribas to serve European and Adjacent Markets
NRx Pharmaceuticals (NASDAQ: NRXP), via its subsidiary, NRx Luxembourg (NRx), has concluded a business mission to Luxembourg at the invitation of the Luxembourg Ministry of the Economy in...
-
November 2, 2021- After Review of More than 300 Enrolled Patients in ACTIV-3b Critical Care Study, No New Safety Concerns Raised by Independent Data Safety Monitoring Board; Study Cleared to Continue Enrollment to Target 640 Patients
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today provided a new safety update on ZYESAMI® (aviptadil), which is being tested in the ACTIV-3b Critical Care...
-
October 14, 2021Seventeen of 21 Patients Treated with Aviptadil Survived to Day 60 Compared to 5 of 24 in the Controlled Group of Patients
NRx Pharmaceuticals (Nasdaq: NRXP), today announced the publication of peer-reviewed results from a prospective, open-label, administratively controlled trial of aviptadil for the treatment of...
-
October 12, 2021
NRx Pharmaceuticals (Nasdaq: NRXP), today announced that a revised Investigational New Drug module on the manufacturing of ZYESAMI™ (aviptadil) was submitted to the US Food and Drug...
-
October 9, 2021--Company to Host Conference Call on Tuesday, November 16, 2021, at 8:30AM ET--
RADNOR, Pa., Nov. 09, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical-stage, global biopharmaceutical company, today announced that management will report...
-
September 29, 2021- After Review of 232 Enrolled Patients in ACTIV-3b Critical Care Study, No New Safety Concerns Raised by Independent Data Safety Monitoring Board
NRx Pharmaceuticals (NRx) (NASDAQ: NRXP), a clinical stage, biopharmaceutical company today provided a safety update on ZYESAMI™ (aviptadil) which is being tested in the ACTIV-3b Critical Care...
-
August 30, 2021- NRx Has Provided Updated Data to US Food and Drug Administration (FDA) in Support of Emergency Use Authorization Request for ZYESAMI™ (aviptadil)
NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced an additional finding in its phase 2b/3 clinical trial investigating ZYESAMI™ (aviptadil) for the treatment of patients with acute Respiratory...
-
August 27, 2021- ZYESAMI™ (aviptadil) Has Previously Demonstrated a Statistically Significant Increase in Survival of Highly Comorbid COVID-19 Patients in Two 60-day Trials
NRx Pharmaceuticals (Nasdaq: NRXP), a clinical stage, biopharmaceutical company, today announced top line data demonstrating improved outcomes at one year in highly comorbid patients with COVID-19...
-
August 26, 2021- Agreement Represents Path to Market for ZYESAMI™, as Time to Treatment is Crucial for Patients
NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has signed an agreement with Cardinal Health to provide third party logistics and distribution of ZYESAMI™ upon the potential...
-
August 24, 2021
NRx Pharmaceuticals (Nasdaq: NRXP), today announced that it has completed its previously announced private placement for the purchase of 2,727,273 shares of common stock. The Company issued to the...
-
August 23, 2021- NRx Pharmaceuticals to lead BriLife Vaccine Trial in Caucasus Region
NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, biopharmaceutical company noted today reports1 in the Israeli media that participants in the BriLife vaccine trial who received the...
-
August 16, 2021- Emergency Use Authorization (EUA) Request for ZYESAMI™ (aviptadil) Pending with United States Food and Drug Administration to Treat Patients Suffering from Critical COVID-19 with Respiratory Failure
NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage biopharmaceutical company today provided a business update and financial results for the quarter ended June 30, 2021. NRx will host a...
Click here to view our corporate presentation or on the image below
![]() |